Bifidobacterium lactis Inhibits iNOS Expression in LPS-stimulated RAW 264.7 Macrophages
Abstract
BACKGROUND: Bifidobacterium is a genus of lactic acid bacteria that lives in the large intestine of humans and animals. The health benefits of this genus are well established; however, the anti-inflammatory activity of this genus, specifically Bifidobacterium lactis, has not been well defined. Therefore, in this study, we evaluated anti-inflammatory activity of B. lactis hydrolysates using lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages.
METHODS: RAW 264.7 cells were cultured using Dulbecco’s Modified Eagle’s Medium in 5 % CO2 incubator at 37 ℃. One µg/mL of LPS was used to stimulate RAW 264.7 cells. Nitric oxide (NO) production, inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) were measured to evaluate anti-inflammatory activity of B. lactis hydrolysates. The cytotoxicity of the inhibitor was also measured in present study through 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay.
RESULTS: The results showed that B. lactis hydrolysates at 25–200 μg/mL inhibited NO production. In concentration-dependent manner, B. lactis hydrolysate showed inhibition of iNOS expression. However, no inhibition on COX-2 expression was observed. The MTS assay of the B. lactis hydrolysates showed no side effects on the cell viability at all concentrations.
CONCLUSION: The current study revealed that B. lactis hydrolysates possess specific anti-inflammatory effects by inhibiting iNOS expression without cytotoxicity and therefore could potentially be developed as a new iNOS inhibitor.
KEYWORDS: Bifidobacterium lactis, macrophages, hydrolysates, iNOS, COX-2
Full Text:
PDFReferences
Guzik TJ, Korbut R, Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol. 2003; 54(4): 469-87, article.
Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 1992; 6(12): 3051-64, CrossRef.
Catherine P, Nicholas WL. Acute and chronic inflammation induces disease pathogenesis. In: Coleman WB, Tsongalis GJ, editors. Molecular Pathology: The Molecular Basis of Human Diseases. 2nd ed. London: Academic Press; 2018. p.25-43, CrossRef.
Zarghi A, Arfaei S. Selective COX-2 inhibitors: A review of their structure-activity relationships. Iran J Pharm Res. 2011; 10(4): 655-83, PMID.
Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Pharmacology. 1994; 91(6): 2046-50, CrossRef.
Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell. 1994; 78(6): 915-8, CrossRef.
Rockey DC, Chung JJ, McKee CM, Noble PW. Stimulation of inducible nitric oxide synthase in rat liver by hyaluronan fragments. Hepatology. 1998; 27(1): 86-92, CrossRef.
Ngkelo A, Meja K, Yeadon M, Adcock I, Kirkham PA. LPS induced inflammatory responses in human peripheral blood mononuclear cells is mediated through NOX4 and Giα dependent PI-3 kinase signalling. J Inflamm (Lond). 2012; 9(1): 1, CrossRef.
Ranuh RG, Athiyyah AF, Darma A, Riawan W, Surono IS, Sandra F, et al. Lactobacillus plantarum IS-20506 probiotic restores galectin-4 and myosin-1a expressions in duodenum, jejunum and ileum of lipopolysaccharide-induced rats. Indones Biomed J. 2020; 12(3): 283-7, CrossRef.
Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997; 57(7): 1276-80, PMID.
Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 1998; 58(22): 4997-5001, PMID.
Da Cunha EF, Ramalho TC, Josa D, Caetano MS, de Souza TC. Targeting inhibition of COX-2: A review of patents, 2002-2006. Recent Pat Inflamm Allergy Drug Discov. 2007; 1(2): 108-23, CrossRef.
Ruiz Rodríguez LG, Aller K, Bru E, De Vuyst L, Hebert EM, Mozzi F. Enhanced mannitol biosynthesis by the fruit origin strain Fructobacillus tropaeoli CRL 2034. Appl. Microbiol. Biotechnol. 2017; 101(15): 6165–177, CrossRef.
Panwar H, Rashmi HM, Batish VK, Grover S. Probiotics as potential biotherapeutics in the management of type 2 diabetes—prospects and perspectives. Diabetes. 2017; 29(2): 103-12, CrossRef.
Claes I, Keersmaecker S, Vanderleyden J, Lebeer S. Lessons from probiotic–host interaction studies in murine models of experimental colitis. Mol Nutr Food Res. 2011; 55(1): 1441-53, CrossRef.
Yu R, Zuo F, Ma H, Chen S. Exopolysaccharide-producing Bifidobacterium adolescentis strains with similar adhesion property induce differential regulation of inflammatory immune response in Treg/Th17 axis of DSS-colitis mice. Nutrients. 2019; 11(4): 782, CrossRef.
Sharma P, Tomar SK, Goswami P, Sangwan V, Singh R. Antibiotic resistance among commercially available probiotics. Food Res Int. 2014; 57: 176-95, CrossRef.
Bellavia M, Rappa F, Lo Bello M, Brecchia G, Tomasello G, Leone A, et al. Lactobacillus casei and Bifidobacterium lactis supplementation reduces tissue damage of intestinal mucosa and liver after 2,4,6- trinitrobenzenesulfonic acid treatment in mice. J Biol Regul Homeost Agents. 2014; 28(2): 251-61, article.
Choi JS, Jang DB, Cho HK, Lee BB, Ha YM, Choi IS. Anti-erythema and anti-edema activities of lactic acid bacteria extracts in mice. Toxicol Environ Health Sci. 2017; 9(1): 82-7, CrossRef.
Garcia LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol. 2020; 11: 1441, CrossRef.
Choi JS, Moon WS, Moon JN, Cheon EJ, Son SW, Kim JW, et al. Cytotoxicity and single-dose oral toxicity testing for rice bran supercritical CO2 extract. Toxicol. Environ. Health. Sci. 2013; 5(4): 215-20, CrossRef.
Purnama CA, Meiliana A, Barliana MI, Dandan KL, Wijaya A. Apoptosis and efferocytosis in inflammatory diseases. Indones Biomed J. 2021; 13(3): 242-55, CrossRef.
Ma KC, Schenck EJ, Pabon MA, Choi AMK. The role of danger signals in the pathogenesis and perpetuation of critical illness. Am J Respir Crit Care Med. 2018; 197(3): 300-9, CrossRef.
Dvorakova M, Landa P. Anti-inflammatory activity of natural stilbenoids: A review. Pharmacological Research. 2017; 124: 126-45, CrossRef.
Lawrence T, Willoughby DA, Gilroy DW. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat. Rev. Immunol. 2002; 2(10): 787-95, CrossRef.
Duque GA, Descoteaux A. Macrophage cytokines: Involvement in immunity and infectious diseases. Front Immunol. 2014; 5: 491, CrossRef.
Megha KB, Joseph X, Akhil V, Mohanan PV. Cascade of immune mechanism and consequences of inflammatory disorders. Phytomedicine. 2021; 91: 153712, CrossRef.
Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013; 16(5): 821-47, CrossRef.
Bjarnason I, Scarpignato C, Holmgren E, Olszewski M, Rainsford KD, Lanas A. Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs. Gastroenterology. 2018; 154(3): 500-14, CrossRef.
Bae I-K, Min H-Y, Han A-R, Seo E-K, Lee SK. Suppression of lipopolysaccharide-induced expression of inducible nitric oxide synthase by brazilin in RAW 264.7 macrophage cells. Eur J Pharmacol. 2005; 513(3): 237-42, CrossRef.
Cheenpracha S, Park E-J, Rostama B, Pezzuto JM, Chang LC. Inhibition of nitric oxide (NO) production in lipopolysaccharide (LPS)-activated murine macrophage RAW 264.7 cells by the norsesterterpene peroxide, epimuqubilin A. Mar Drugs. 2010; 8(3): 429-37, CrossRef.
Nordin NS, Keong YY, Tohid SFM, Zain ZNM, Hakim MN. In vitro anti-inflammatory evaluation of 6-thioguanine and 6-hydroxy-2-mercaptopurine as a potential treatment for rheumatoid arthritis. Indones Biomed J. 2021; 13(4): 383-95, CrossRef.
Hobbs JM, Vazquez AR, Remijan ND, Trotter RE, McMillan TV, Freedman KE, et al. Evaluation of pharmacokinetics and acute anti-inflammatory potential of two oral cannabidiol preparations in healthy adults. Phytother Res. 2020; 34(7): 1696-703, CrossRef.
Fretland DJ, Connor JR, Pitzele BS, Currie MG, Manning PT. Inhibition of nitric oxide synthase and prospects for therapy in inflammatory diseases. Curr Pharm Des. 1997; 3: 447-62, CrossRef.
Landino LM, Crews BC, Timmons MD, Morrow JD, Marnett LJ. Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proc Natl Acad Sci USA. 1996; 93(26): 15069-74, CrossRef.
Needleman P, Manning PT. Interactions between the inducible cyclooxygenase (COX-2) and nitric oxide synthase (iNOS) pathways: Implications for therapeutic intervention in osteoarthritis. Osteoarthr. Cartil. 1999; 7(4): 367-70, CrossRef.
Amarante-Mendes GP, Adjemian S, Branco LM, Zanetti LC, Weinlich R, Bortoluci KR. Pattern recognition receptors and the host cell death molecular machinery. Front Immunol. 2018; 9: 2379, CrossRef.
Cristofori F, Dargenio VN, Dargenio C, Miniello VL, Barone M, Francavilla R. Anti-inflammatory and immunomodulatory effects of probiotics in gut inflammation: A door to the body. Front Immunol. 2021; 12: 578386, CrossRef.
Harris RC. COX-2 and the kidney. J Cardiovasc Pharmacol. 2006; 47(Suppl 1): S37-42, CrossRef.
Yin HM, Wang SN, Nie SP, Xie MY. Coix polysaccharides: Gut microbiota regulation and immunomodulatory. Bioact Carbohydr and Diet Fibre. 2018; 16: 53-61, CrossRef.
DOI: https://doi.org/10.18585/inabj.v14i2.1929
Copyright (c) 2022 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
